ICMR-NIN Study Reveals Vitamin D3 Superiority for Muscle and Cardiac Health

The differential potency reading has direct operational weight for any fortification program selecting between the two isoforms at the formulation stage.

Trial design and dietary matrix

The study assigned weaning male Sprague-Dawley rats to one of four diets: vitamin D2, vitamin D3, a D2+D3 blend, and a vitamin D-deficient baseline. Outcome measurements covered body composition, grip strength, skeletal muscle fibre cross-sectional area, and molecular markers tied to muscle development and energy metabolism. Cardiac assessment tracked contractility and metabolism markers. Both a maintenance phase and a recovery phase following deficiency were run. The largest isoform separation appeared in the recovery arm.

Differential potency across tissue endpoints

D3 cohorts registered greater gains in muscle mass, fibre size, and grip strength relative to D2. D3 also produced stronger readings on markers linked to muscle differentiation and metabolic throughput. The cardiac panel followed the same pattern, with higher contractility marker activity and metabolic marker expression in the D3 group.

Calcium-related parameters responded to both isoforms. The divergence appeared in the structural and metabolic tissue endpoints, not in mineral homeostasis.

Dr Ayesha Ismail, Scientist F at ICMR-NIN and corresponding author, stated that both forms corrected calcium-related parameters but D2 lagged on muscle and heart structure and energy metabolism.

Dr Bharati Kulkarni, Director, ICMR-NIN, noted the findings indicate D3 may be more effective at maintaining and restoring skeletal muscle and cardiac functions. She stressed that human translation requires further study before supplementation and fortification programmes adjust their protocols.

Verification points before any matrix switch

• The model is a rodent depletion-repletion design. Tissue-specific potency in rats does not auto-translate to human fortification matrices.
• D2 and D3 show different degradation rates under extrusion, spray-drying, and oil-phase encapsulation. Any substitution at the formulation stage requires re-running stability assays under the specific processing conditions of the carrier food.
• Bioavailability yield from fortified vehicles remains dependent on the fat content of the matrix. Higher potency per unit does not eliminate the need for fat-soluble delivery optimization.
• National fortification standards and procurement specifications that currently list D2 as the active form should be flagged for review against this tissue-level evidence, with implementation held until human dosing data is available.

Cost-benefit summary: the study supplies a tissue-endpoint rationale favoring D3, but the rat model, the absence of human equivalence data, and the unverified processing-stability differential between the two isoforms under specific carrier conditions mean a formulation switch is premature. The actionable step at this stage is a stability and bioavailability re-screen of D3 within the target food matrix, not a procurement change.